Published in Mol Endocrinol on December 18, 2003
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A (2006) 1.75
Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function. J Clin Endocrinol Metab (2007) 1.71
Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet (2009) 1.32
Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat (2008) 1.18
Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor. Mol Cell Biol (2005) 1.13
Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem (2012) 1.13
Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor alpha. Nucl Recept Signal (2006) 0.90
Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol (2013) 0.87
Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients. Int J Mol Sci (2013) 0.82
Expression of androgen receptor and its phosphorylated forms in breast cancer progression. Cancer (2013) 0.80
Quantitative methods to analyze subnuclear protein organization in cell populations with varying degrees of protein expression. J Biomed Opt (2005) 0.80
Ubiquitin Specific Protease 26 (USP26) expression analysis in human testicular and extragonadal tissues indicates diverse action of USP26 in cell differentiation and tumorigenesis. PLoS One (2014) 0.78
Genetic variations in the androgen receptor are associated with steroid concentrations and anthropometrics but not with muscle mass in healthy young men. PLoS One (2014) 0.77
Identification of androgen receptor phosphorylation in the primate ovary in vivo. Reproduction (2010) 0.77
Proline-Directed Androgen Receptor Phosphorylation. J Mol Genet Med (2013) 0.76
Multiple exportins influence thyroid hormone receptor localization. Mol Cell Endocrinol (2015) 0.76
Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res (2017) 0.75
Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic (2005) 3.83
Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA (2005) 3.29
Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care (2004) 2.84
PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol (2003) 2.20
Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointest Endosc (2005) 2.18
Continual reassessment method for partial ordering. Biometrics (2011) 2.11
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res (2002) 2.01
Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem (2002) 2.01
Profiling the evolution of human metastatic bladder cancer. Cancer Res (2004) 2.00
Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood (2012) 1.95
Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol Cell Biol (2002) 1.88
Matrix rigidity regulates cancer cell growth and cellular phenotype. PLoS One (2010) 1.70
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem (2007) 1.65
Dose-finding design for multi-drug combinations. Clin Trials (2011) 1.63
Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol (2005) 1.62
Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). J Am Diet Assoc (2007) 1.62
Ras signaling in prostate cancer progression. J Cell Biochem (2004) 1.62
Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J Biol Chem (2003) 1.60
Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res (2006) 1.56
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res (2003) 1.56
Multifactor clinical score and outcome of mechanical ventilation weaning trials: Burns Wean Assessment Program. Am J Crit Care (2010) 1.50
Retrotranslocation of the chaperone calreticulin from the endoplasmic reticulum lumen to the cytosol. Mol Cell Biol (2005) 1.48
Karyopherin alpha7 (KPNA7), a divergent member of the importin alpha family of nuclear import receptors. BMC Cell Biol (2010) 1.36
FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol (2010) 1.36
CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol (2010) 1.35
Phosphorylation of a conserved serine in the deoxyribonucleic acid binding domain of nuclear receptors alters intracellular localization. Mol Endocrinol (2007) 1.32
SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol Endocrinol (2008) 1.32
Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke (2011) 1.32
Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharm Stat (2013) 1.26
Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke (2009) 1.24
Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res (2003) 1.23
The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res (2009) 1.22
Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol Cell Biol (2004) 1.21
Post-translational modification of the androgen receptor. Mol Cell Endocrinol (2011) 1.21
Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem (2009) 1.19
Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu Rev Physiol (2007) 1.17
Ca2+-dependent nuclear export mediated by calreticulin. Mol Cell Biol (2002) 1.17
The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem (2004) 1.14
Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor. Mol Cell Biol (2005) 1.13
Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. Proc Natl Acad Sci U S A (2004) 1.11
Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol (2003) 1.11
The defective nuclear lamina in Hutchinson-gilford progeria syndrome disrupts the nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9. Mol Cell Biol (2011) 1.09
Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction. Mol Cell Biol (2008) 1.09
Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther (2011) 1.09
RACK1 targets the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to link integrin engagement with focal adhesion disassembly and cell motility. Mol Cell Biol (2007) 1.09
Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve (2008) 1.08
Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui. Stat Med (2014) 1.06
Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res (2010) 1.05
Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget (2013) 1.04
Mechanisms, clinical presentations, injuries, and outcomes from inflicted versus noninflicted head trauma during infancy: results of a prospective, multicentered, comparative study. Pediatrics (2007) 1.03
Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther (2013) 1.03
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res (2009) 1.02
Percutaneous injuries before and after the Needlestick Safety and Prevention Act. N Engl J Med (2012) 1.00
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res (2013) 1.00
Predicting rural practice using different definitions to classify medical school applicants as having a rural upbringing. J Rural Health (2007) 0.98
Regulation of nuclear import and export by the GTPase Ran. Int Rev Cytol (2002) 0.98
Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve (2008) 0.97
The novel Cdc42 guanine nucleotide exchange factor, zizimin1, dimerizes via the Cdc42-binding CZH2 domain. J Biol Chem (2004) 0.97
Performance of two-stage continual reassessment method relative to an optimal benchmark. Clin Trials (2013) 0.97
Dobutamine response and myocardial infarct transmurality: functional improvement after coronary artery bypass grafting--initial experience. Radiology (2006) 0.96
Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol Cell Biol (2007) 0.95
Influence of hemoglobin levels on inpatient rehabilitation outcomes after total knee arthroplasty. J Arthroplasty (2006) 0.95
Using the time-to-event continual reassessment method in the presence of partial orders. Stat Med (2012) 0.95
Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. PLoS One (2012) 0.92
Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro. J Biol Chem (2008) 0.92
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther (2012) 0.92
PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. Hum Pathol (2009) 0.92
Nuclear transport of steroid hormone receptors. Crit Rev Eukaryot Gene Expr (2005) 0.92
Statin therapy improves outcomes after valvular heart surgery. Ann Thorac Surg (2008) 0.92
Phase I/II adaptive design for drug combination oncology trials. Stat Med (2014) 0.92
Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol Endocrinol (2007) 0.91
Clinical and consumer trial performance of a sensitive immunodiagnostic home test that qualitatively detects low concentrations of sperm following vasectomy. J Urol (2008) 0.91
Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J Biol Chem (2010) 0.91
Intranuclear organization and function of the androgen receptor. Trends Endocrinol Metab (2004) 0.90
Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve (2010) 0.89
Hyperosmotic stress signaling to the nucleus disrupts the Ran gradient and the production of RanGTP. Mol Biol Cell (2007) 0.89